Engineered T-Cells take on tough leukemias in early trial
NCT ID NCT02159495
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm that has returned or not responded to treatment. The therapy involves taking a patient's own (or a donor's) immune cells, genetically modifying them to recognize and attack cancer cells carrying a protein called CD123, and infusing them back after chemotherapy. The main goals are to find the safest dose and to see if the treatment can shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Genetically modified T-cells (CD123CAR-CD28-CD3zeta-EGFRt-expressing T lymphocytes)
What this could lead to
If it works, this could point toward a new treatment option for patients with hard-to-treat leukemias that have come back or not responded to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 31 participants, so it is primarily testing safety and dosing. The treatment may not work for everyone, and there are risks of serious side effects from the chemotherapy and the modified cells.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.